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EDUCATIONAL OBJECTIVES
After reading this course, the participant
should be able to:
1. Define synthetic
cannabinoids and their drug
classification.
 2. Discuss the adverse effects
of synthetic cannabinoid use.
 3. Identify the rising
prevalence of medical events
related to the toxicity of this
class of drugs.
 
Effects of Synthetic Cannabinoid Use
 DARRENMOWER/E+/GETTY IMAGES PLUS 
Oral health professionals need to be aware of the systemic and oral health effects of the
substances in this class of drugs.
By Susan Davide, RDH, MS, MSEd
Synthetic cannabinoids are man-made drugs manufactured to resemble the chemicals in
marijuana plants.1 The chemicals are sprayed onto plant material, which is then smoked or
converted into liquid to be vaped, similar to how marijuana is used.2 Synthetic cannabinoids may
be purchased legally because drug manufacturers constantly change the chemical structure to
circumvent drug laws.1,3 While marketed as safe and legal alternatives to marijuana, synthetic
cannabinoids exert significant effects on the brain, causing a host of negative side effects,
including acute toxicity and possible death.1–12 
The use of synthetic cannabinoids is undetectable by traditional drug testing, giving it a
reputation as a “legal high” and making it an attractive substitute to marijuana.1,3 Oral health
professionals are in a unique position to educate patients and the public about synthetic
cannabinoid use and its adverse effects, including oral health effects, while also providing
resources and referral for intervention.
 
DRUG CLASSIFICATION AND METHODS OF CONSUMPTION
Synthetic cannabinoids are classified as new psychoactive substances (NPS), which are
recently introduced mind-altering chemicals designed to imitate common illegal drugs.2 These
synthetic versions mimic the pharmacological effects of the original substance, while avoiding
classification as illegal.2,13–16 
A variety of consumption methods are available for synthetic cannabinoids, such as smoked in
joints and/or pipes, ingested, used in tea, and vaporized and inhaled in e-cigarettes or through
the mouth and nose. Manufacturers sell these herbal incense products in colorful foil packages
and liquid incense products, marketing them under myriad names to appeal to young people.
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TABLE 1. Serious Adverse Health Effects That Can Be Caused by
Synthetic Cannabinoid Use2,12,13 
Synthetic cannabinoids may be called K2, spice, joker, black mamba, kush, and chronic.2,13
Most NPSs are manufactured in China without regulation and then smuggled into the United
States.13,15 They are sold via the internet, in head shops (stores selling drug-related
paraphernalia), smoke shops, convenience stores, and gas stations.13,14 NPS use is popular
among athletes, soldiers, and parolees, because they can be consumed without being detected
on the mandatory drug tests common among these populations.7,16 
 
HISTORY
Decades ago, synthetic cannabinoids were created and used for
experimental and pharmaceutical purposes. Currently, two canna binoid-
based drugs—dronabinol and nabilone—are approved by the federal
Food and Drug Administration and legally produced and prescribed.10
Ingested in pill form, dronabinol and nabilone are prescribed to address
the vomiting/nausea caused by cancer therapy. Dronabinol is also used to
improve the appetite of those with the human immunodeficiency virus.
The types of synthetic cannabinoids used recreationally include the HU-
210 series developed by Hebrew University of Jerusalem in the 1960s; the
cyclohexyl phenol series developed and named after Charles Pfizer of
Pfizer Pharmaceuticals in the 1970s; and the JWH series developed and
named for John W. Huffman, PhD, of Clemson University in the
1990s.10,14 Synthetic cannabinoid use for nonmedical purposes became
popular in Europe in 2004 and then in the US in 2008.1,3,9,15 
Since 2009, more than 300 NPSs have been identified, with approximately
95 different synthetic cannabinoids being sold as legal alternatives to
cannabis.13 A primary misconception is that these drugs are natural, legal,
safe, and produce fewer side effects than marijuana.15 
 
PHARMACODYNAMICS
Most synthetic cannabinoids have a greater binding affinity to the cannabinoid receptor CB1 receptor than does 9-tetrahydrocannabinol
(THC)—the primary psychoactive compound in the cannabis plant. Synthetic cannabinoids also have a greater affinity to the CB1
receptor than to the CB2 receptor.16 Cannabinoid receptors, located throughout the body, are part of the endocannabinoid system,
which is involved in a variety of physiological processes, including appetite, pain/sensation, mood, and memory.15,16 When synthetic
cannabinoids activate CB1 (psychoactive effects) or CB2 receptors (anti-inflammatory effects), they change the way the body functions.
In vitro and animal in vivo studies show synthetic cannabinoid pharmacological effects are two times to 100 times more potent than
THC.16 Synthetic cannabinoids produce physiological and psychoactive effects similar to THC but with greater intensity, which may
result in medical and psychiatric emergencies.
Due to the negative effects of these drugs, many users prefer cannabis over synthetic cannabinoids.16 Long-term and residual ef fects
are unknown, and there is a need for drug-detection tests made specifically for the detection of synthetic cannabinoids.16,17 
 
SYSTEMIC HEALTH EFFECTS AND TOXICITY
Many federal, state, and local government officials have determined that synthetic drug use is a public health threat. Users don’t know
what they are consuming, leaving them unaware of health or addiction risks.9,12 Synthetic cannabinoids produce similar effects to
cannabis, such as elevated mood, relaxation, altered perception, and symptoms of psychosis, while also bearing the risk of serious
adverse health effects (Table 1).2,12,13 
In 2010, the American College of Medical Toxicology established the ToxIC Case Registry to survey and research toxicology.9
Participating sites record basic data on patients who have been treated by medical toxicologists. Among 456 cases of synthetic
cannabinoid intoxication treated by US medical toxicologists between 2010 and 2015, 277 noted synthetic cannabinoids as the sole
toxicologic agent.9 Of these cases, three deaths were attributed solely to synthetic cannabinoids, in addition to two deaths attributed to
exposure to multiple agents. During this same period, the number of synthetic cannabinoid poisonings increased across the US.9 
According to the American Association of Poison Control Centers (AAPCC), poison control centers around the US received 7,779 calls
related to synthetic cannabinoid substances in 2015, more than double the number of calls received in 2014 (Figure 1).12 The number of
calls decreased from 2011 to 2013, most likely due to the passage of the Synthetic Drug Abuse Prevention Act of 2012. The act added
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FIGURE 1. Calls to poison control centers about synthetic cannabinoid
use. 
certain synthetic cannabinoids to Schedule I of the Controlled Substances
Act.14 Current AAPCC data for 2017 indicate 186 reports of exposure to
synthetic cannabinoids made during the month of January.12 
States across the country have been experiencing an uptick in adverse
medical events associated with synthetic cannabinoid use. In September
2013, 76 patients—mostly young men—visited emergency departments in
Aurora, Colorado, due to toxic exposure to black mamba, a type of
synthetic cannabinoid.6 Those affected experienced altered mental status
and tachycardia followed by brachycardia. Most were treated in the
emergency department, but seven required admission to intensive care
units. Product analysis confirmed the offending substance was a molecule
known as ADB-PINACA, a novel synthetic cannabinoid.6 Exposure to this
substance was associated with neurotoxicity and cardiotoxicity; however,
evolving types of synthetic cannabinoids have been associated with
seizures, ischemic stroke, cardiac toxicity, and acute kidney
failure.6,9,11,14,16 
From April 2 to May 3, 2015, the University of Mississippi Medical Center (UMMC) reported 721 reported cases associated with
synthetic cannabinoid use, including nine deaths. Patients were mostly men and ranged in age from 14 to 62 (median age of 31).5 Most
patients were treated and released by the UMMC emergency department, but 13 were admitted to general inpatient services and 12
were admitted to intensive care units. Vital signs information was available for 115 patients, with 48 reporting tachycardia (heart rate
>100 beats per minute) and 35 noting elevated (>140 mmHg) systolic blood pressure. A portion of patients exhibited aggressive or
violent behavior, agitation/aggression, depression, or confusion.
Anchorage, Alaska, experienced an outbreak of adverse reactions related to synthetic canna binoid use from July 2015 to March 2016.
During this period, 1,351 emergency department visits were due to synthetic canna binoid use. The investigation found 11 different
synthetic cannabinoids chemicals circulating during the outbreak. Passage of ordinance AO2015-123(S) raised criminal penalties
associated with possession, use, and sale of synthetic cannabinoids, resulting in a significant decline in the number of patients seeking
treatment for synthetic cannabinoid use following its passage.8 
New York City has also experienced an increase in synthetic cannabinoid-related emergency department visits, despite a notable
decrease in use following passage of legislation in 2015 that makes it illegal to possess, sell, offer to sell, or manufacture synthetic
cannabinoids, and the implementation of other public health campaigns.4 Since January 2015, the city’s Department of Health and
Mental Hygiene has noted more than 8,000 synthetic cannabinoid-related emergency department visits with 10 documented mortalities;
nine of which involved multiple substances.4 Approximately 90% of those affected were men and 99% were age 18 or older with a
median age of 37.
In 2016, a team of researchers from the University of Arkansas received a $2.7 million grant from the National Institutes of Health and
National Institute on Drug Abuse to conduct the first comprehensive study on the dangers posed by synthetic cannabinoids.18 The
purpose of the 5-year study is to determine the toxicity of man-made cannabinoids, possible antidotes for toxicity, and create an
educational campaign promoting the fact that synthetic cannabinoids do not provide a safe alternative to marijuana.18 
 
PROCESS OF CARE AND ORAL HEALTH IMPLICATIONS
The dental hygiene process of care includes assessment, dental hygiene diagnosis, planning, implementation, evaluation, and
documentation.19 During the assessment phase, oral health professionals should ask questions, such as whether the patient uses any
form of tobacco or marijuana, frequency and amount of use, and interest in quitting. Other screening tools include the Cage
Questionnaire20 and the Five A’s Model (Ask, Advise, Assess, Assist, and Arrange).21 These are most effective when used while taking
a routine medical history.
Health care providers need to be familiar with synthetic cannabinoids so they can provide information and referral for treatment and/or
intervention. Indicators of recent synthetic cannabinoid use may include conjunctival injection (red sclera); breath with a smoky, chemical
smell; tachycardia; hypertension; light headedness; and headache.22 Similar to tobacco and marijuana use, patients who consume
synthetic cannabinoids are at increased risk of xerostomia, which is associated with increased caries risk, staining, and oral malodor.23
Chronic smoking can create inflammation of the oral epithelium, leukoplakia, periodontal diseases, and delay wound healing.23
Marijuana users tend to have poor oral hygiene compared with nonusers and this may also be true for synthetic cannabinoid users.21 
Vital signs are often increased with marijuana use and careful intra- and extraoral examination may include signs, such as lack of oral
hygiene; dilated pupils; red, inflamed, or bloodshot eyes; mucosal dryness; heavy biofilm; moderate to severe gingival inflammation; and
caries.22 Patients with substance abuse problems tend to delay dental care, which is reflected in their oral health status.21 Following an
assessment, the next steps include composing a dental hygiene diagnosis, identifying priorities based on the patient’s needs, and
discussing these findings with the patients. Patients should be educated on the importance of biofilm control and how to effectively
accomplish this at home. Oral health professionals must be aware of the characteristics that suggest possible use of synthetic
cannabinoids and provide an appropriate dental hygiene care plan and education regarding the negative health effects of usage.
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TABLE 2. Resources for Addressing Drug Use and Addiction 
 
PREVENTION AND TREATMENT PROGRAMS
The federal government has instituted several national drug prevention
programs designed to reach targeted populations through public service
announcements, grant opportunities, educational programs, and the
sharing of expertise. Many local and state governments have also created
prevention programs tailored to address specific problems and needs.
Law enforcement agencies, military branches, businesses, faith-based
institutions, civic organizations, and private foundations are also active
forces in drug abuse prevention.13 Table 2 provides a list of some of these
resources.
Oral health professionals should compile a list of local drug prevention
and treatment agencies and programs to provide to patients. A 1-page
fact sheet on synthetic cannabinoid use, similar to educational resources
regarding tobacco/smoking, may be disseminated in dental practices.
 
CONCLUSION
The increasing popularity of synthetic cannabinoids use requires oral
health professionals to be aware of the health effects of these substances.
By remaining up-to-date on current trends of alternative recreational drug
use, oral health professionals will be better able to detect early clinical
signs of unhealthy lifestyles, including po tential synthetic can nabinoid use
and provide referrals and intervention resources. Clinicians should
conduct a thorough medical and dental history that assesses social
behaviors in addition to vital signs and performing an extraoral and
intraoral examination. This will assist in implementing appropriate
treatment and intervention strategies. Ultimately, the goal of oral health
professionals is to provide appropriate oral treatment; educate and
improve patients’ health literacy; and assist in motivating patients to
address substance misuse in order to improve oral and systemic health outcomes.21,23 
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